Literature DB >> 19283769

Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.

Naveed Shaik1, Nagdeep Giri, William F Elmquist.   

Abstract

The objective of this study was: (1) to characterize the P-gp inhibitory effect of different concentrations of Pluronic P85 on anti-HIV-1 drug cellular accumulation, and (2) to investigate the relationship between cellular accumulation and free fraction of drug. Cellular accumulation studies in MDCKII-WT and MDCKII-MDR1 cell monolayers showed a biphasic dose response characterized by decline in accumulation at Pluronic concentrations greater than the CMC. This phenomenon was independent of the inhibition of P-gp efflux by Pluronic. Cell-free equilibrium dialysis was used to determine the effect of Pluronic P85 on drug free fraction and the affinity of Pluronic micelles for drug was modeled. Nelfinavir and saquinavir associated extensively with micelles and equilibrium free fractions were low at P85 concentrations above the CMC, with association constants being in the order nelfinavir > saquinavir >>> abacavir. Abacavir, a P-gp substrate, showed no association with micelles yet showed a biphasic response in cellular accumulation. These data suggest that, above the CMC, inhibition of P-gp is not affected but rather factors such as micellar trapping could contribute to decreased accumulation. Therefore, the in vitro evaluation of the effect of Pluronic formulations on active transport should take into account both the physicochemical properties of drug and the composition of Pluronic. (c) 2009 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19283769      PMCID: PMC2755653          DOI: 10.1002/jps.21723

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  46 in total

Review 1.  Solubilizing excipients in oral and injectable formulations.

Authors:  Robert G Strickley
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

2.  Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells.

Authors:  E Batrakova; S Lee; S Li; A Venne; V Alakhov; A Kabanov
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

3.  Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers.

Authors:  E V Batrakova; S Li; D W Miller; A V Kabanov
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

4.  Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization.

Authors:  E V Batrakova; S Li; S V Vinogradov; V Y Alakhov; D W Miller; A V Kabanov
Journal:  J Pharmacol Exp Ther       Date:  2001-11       Impact factor: 4.030

5.  Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells.

Authors:  Elena V Batrakova; Shu Li; Valery Yu Alakhov; Donald W Miller; Alexander V Kabanov
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

6.  Evidence for modulation of P-glycoprotein-mediated efflux by methoxypolyethylene glycol-block-Polycaprolactone amphiphilic diblock copolymers.

Authors:  Jason Zastre; John Jackson; Helen Burt
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

7.  Reversal of multi-drug resistance in vitro by fatty acid-PEG-fatty acid diesters.

Authors:  L E Buckingham; M Balasubramanian; A R Safa; H Shah; P Komarov; R M Emanuele; J S Coon
Journal:  Int J Cancer       Date:  1996-01-03       Impact factor: 7.396

8.  Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.

Authors:  D J Boote; I F Dennis; P R Twentyman; R J Osborne; C Laburte; S Hensel; J F Smyth; M H Brampton; N M Bleehen
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

9.  Reversal of multidrug resistance by surfactants.

Authors:  D M Woodcock; M E Linsenmeyer; G Chojnowski; A B Kriegler; V Nink; L K Webster; W H Sawyer
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

10.  The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.

Authors:  M M Malingré; J H Schellens; O Van Tellingen; M Ouwehand; H A Bardelmeijer; H Rosing; F J Koopman; M E Schot; W W Ten Bokkel Huinink; J H Beijnen
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

View more
  4 in total

1.  The Effects of Pharmaceutical Excipients on Gastrointestinal Tract Metabolic Enzymes and Transporters-an Update.

Authors:  Wenpeng Zhang; Yanyan Li; Peng Zou; Man Wu; Zhenqing Zhang; Tao Zhang
Journal:  AAPS J       Date:  2016-05-16       Impact factor: 4.009

2.  Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.

Authors:  Ramola Sane; Rajendar K Mittapalli; William F Elmquist
Journal:  J Pharm Sci       Date:  2013-01-18       Impact factor: 3.534

3.  Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug.

Authors:  Lisa Sanderson; Marcelo da Silva; Gayathri N Sekhar; Rachel C Brown; Hollie Burrell-Saward; Mehmet Fidanboylu; Bo Liu; Lea Ann Dailey; Cécile A Dreiss; Chris Lorenz; Mark Christie; Shanta J Persaud; Vanessa Yardley; Simon L Croft; Margarita Valero; Sarah A Thomas
Journal:  PLoS Negl Trop Dis       Date:  2021-04-15

Review 4.  Muscle membrane integrity in Duchenne muscular dystrophy: recent advances in copolymer-based muscle membrane stabilizers.

Authors:  Evelyne M Houang; Yuk Y Sham; Frank S Bates; Joseph M Metzger
Journal:  Skelet Muscle       Date:  2018-10-10       Impact factor: 4.912

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.